ECO Animal Health Grants Executive LTIP Awards

UK-listed livestock biopharmaceutical leader ECO Animal Health Group plc (AIM: EAH) announced the formal grant of conditional share options and restricted share units (RSUs) to its key executive directors under the company’s Long-Term Incentive Plan (LTIP). The equity awards explicitly tie executive compensation to Total Shareholder Return (TSR) performance benchmarks and key R&D pipeline delivery goals.

Pipeline Focus & Financial Context

• Strategic R&D Focus: The awards align executive performance directly with the commercial expansion of ECO’s self-funded R&D pipeline, prioritizing biologicals and preventive animal health solutions.

• Commercial Anchors: ECO continues to derive significant revenue from its lead proprietary macrolide antibiotic, Aivlosin®, distributed across more than 70 global markets for swine and poultry respiratory and enteric diseases.

• Vaccine Platform Expansion: The compensation structure supports the global rollout of ECOVAXXIN® MS, the company’s novel poultry vaccine targeting Mycoplasma synoviae, which entered the European Union market in mid-2026.